XOMIVI
Live / Applied — Non-final action mailed (as of 07 Nov 2026)
Now
Refused for now — an office action was mailed 07 Nov 2026.
A response is due by 07 Feb 2027; with no response the application is abandoned.
What this means for you
Not registered yet, but its 25 Sept 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 50130174
- Mark type
- Word mark
- Filed
- 25 Sept 2026
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the prevention and treatment of obesity, cancer, osteoporosis, and inflammatory, autoimmune, cardiovascular, and blood diseases and disorders; Pharmaceutical and biological preparations for the prevention and treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiometabolic, genitourinary, oncological, hepatological, ophthalmic, otolaryngological, respiratory, neurological, nephrological, hematological, hormonal, dermatological, and immune system-related diseases and disorders; Pharmaceutical preparations
Owner
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 07 Nov 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 07 Nov 2026 — NON-FINAL ACTION E-MAILED
- 07 Nov 2026 — NON-FINAL ACTION WRITTEN
- 27 Oct 2026 — ASSIGNED TO EXAMINER
- 25 Sept 2026 — APPLICATION FILING RECEIPT MAILED
- 25 Sept 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 25 Sept 2026 — NEW APPLICATION ENTERED